Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Authors||B. Han, T. Chu, J. Qian, B. Yan, Y. Zhang, Q. Chang|
|Title||Preliminary Results of Second Generation ALK Inhibitor PLB1003: A Phase La Study|
|Abstract Text||Journal of Thoracic Oncology, Volume 14, Issue 10, S651|
|Molecular Profile||Treatment Approach|
|Gene Name||Source||Synonyms||Protein Domains||Gene Description||Gene Role|
|Therapy Name||Drugs||Efficacy Evidence||Clinical Trials|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|PLB1003||PLB 1003|PLB-1003||ALK Inhibitor 29||PLB1003 is a small molecule inhibitor of Alk that potentially leads to tumor growth inhibition (Journal of Thoracic Oncology, Volume 14, Issue 10, S651).|
|Gene||Variant||Impact||Protein Effect||Variant Description||Associated with drug Resistance|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|ALK rearrange||lung non-small cell carcinoma||predicted - sensitive||PLB1003||Phase I||Actionable||In a Phase Ia trial, PLB1003 demonstrated safety and preliminary efficacy, resulted in a disease control rate of 86% (12/14, 10 partial response, 2 stable disease) in patients with ALK-rearranged non-small cell lung cancer who progressed on or did not tolerate previous treatment (Journal of Thoracic Oncology, Volume 14, Issue 10, S651).||detail...|